XOMA Corporation (XOMA) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of XOMA Corporation (NASDAQ:XOMA) from a buy rating to a hold rating in a report published on Tuesday.

According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “

Several other research firms also recently issued reports on XOMA. HC Wainwright started coverage on shares of XOMA Corporation in a report on Monday, June 12th. They set a buy rating and a $15.00 price objective for the company. ValuEngine raised shares of XOMA Corporation from a strong sell rating to a sell rating in a report on Wednesday, July 12th. Finally, Wedbush reaffirmed a hold rating on shares of XOMA Corporation in a report on Monday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. XOMA Corporation presently has an average rating of Hold and a consensus price target of $10.67.

Shares of XOMA Corporation (XOMA) opened at 7.47 on Tuesday. The stock’s market cap is $56.76 million. XOMA Corporation has a 1-year low of $3.96 and a 1-year high of $14.00. The company’s 50-day moving average is $7.24 and its 200 day moving average is $6.37.

TRADEMARK VIOLATION NOTICE: “XOMA Corporation (XOMA) Downgraded by Zacks Investment Research” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/08/18/xoma-corporation-xoma-downgraded-by-zacks-investment-research.html.

A hedge fund recently bought a new stake in XOMA Corporation stock. Stonepine Capital Management LLC acquired a new stake in XOMA Corporation (NASDAQ:XOMA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 87,960 shares of the biotechnology company’s stock, valued at approximately $625,000. XOMA Corporation makes up approximately 0.4% of Stonepine Capital Management LLC’s holdings, making the stock its 19th largest position. Stonepine Capital Management LLC owned about 1.17% of XOMA Corporation at the end of the most recent quarter. Institutional investors and hedge funds own 31.30% of the company’s stock.

About XOMA Corporation

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Get a free copy of the Zacks research report on XOMA Corporation (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about XOMA Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for XOMA Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit